HSD17B13 and metabolic dysfunction-associated steatotic liver disease: These results suggested that the higher levels of HSD17B13 in the liver plays a pathogenic role in the occurrence and progression of NAFLD via lipid metabolism- and inflammation-related pathways, and therefore, down-regulating the high level of HSD17B13 might be a strategy to prevent the occurrence of NAFLD and to attenuate the progressive NAFLD.